[CMIP Membership Roster] [CMIP Meeting Rosters]

The CMIP Study Section reviews the development, synthesis, selection, optimization, and validation of novel diagnostic, therapeutic pharmaceuticals or molecular signatures intended for use in translational and clinical imaging studies. The emphasis is on targeting, metabolism, effectiveness, toxicology, biodistribution, breakdown products and pathological findings for imaging cells, tissues, organs, or whole body in animals and humans. These studies often involve radiochemistry, pharmacokinetics, and pharmacodynamics. Specific areas covered by CMIP:

• The development of targeted MRI probes, using paramagnetic, nanoparticle, hyperpolarized or other contrast mechanisms, and the development of instrumentation that is uniquely required for probe-based imaging.
• The development of targeted molecular imaging agents detectable with X-ray based modalities.
• Development of targeted optical imaging agents, including fluorescence, bioluminescence, photosensitizer, and agents for photoacoustic imaging.
• Development of diagnostic and therapeutic agents and carriers including radiopharmaceutical agents.
• Novel reporter gene strategies for imaging of gene expression and inter-molecular interactions in vivo.
• Live cell imaging including cell trafficking, improved labeling methods, mechanistic studies, physiologic processes, and distribution.
• Translational and clinical toxicity, as well as biodistribution of agents and their breakdown products, which may involve radiochemistry, pharmacokinetic and pharmacodynamic studies of imaging agents.
  
  

Study sections with most closely related areas of similar science listed in rank order are:

Medical Imaging [MEDI]
Biomedical  Imaging Technology [BMIT]
Microscopic Imaging [MI]   
Radiation Therapy and Radiopharmaceuticals [RTB] 
Synthetic and Biological Chemistry A [SBCA]
Synthetic and Biological Chemistry B [SBCB]